Pegloticase

uricase covalently attached to polyethylene glycol, modifying 71% of amino groups & retaining 11% of activity without eliciting antibody response in mice or man; used for lowering serum uric acid

Also Known As:

Networked: 131 relevant articles (27 outcomes, 44 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Lipsky, Peter E: 13 articles (05/2022 - 08/2011)
2.	Sundy, John S: 11 articles (12/2014 - 01/2006)
3.	Yeo, Anthony E: 10 articles (05/2022 - 01/2017)
4.	Baraf, Herbert S B: 9 articles (01/2022 - 09/2008)
5.	Edwards, N Lawrence: 8 articles (01/2022 - 08/2011)
6.	LaMoreaux, Brian: 7 articles (04/2022 - 12/2018)
7.	Botson, John K: 6 articles (11/2022 - 06/2020)
8.	Schlesinger, Naomi: 6 articles (01/2022 - 06/2009)
9.	Becker, Michael A: 6 articles (12/2014 - 09/2008)
10.	Keenan, Robert T: 5 articles (05/2022 - 01/2017)

Related Diseases

1.	Gout 01/01/2020 - "Results from patients treated with pegloticase or placebo in two randomized clinical trials and their open-label extension were assessed using a novel evidence-based Gout Multivariable Improvement Measure (GMIM) derived from previously reported criteria for remission and complete response. " 10/20/2014 - "This study showed pegloticase is probably beneficial in the management of tophi in gout, in terms of resolution of tophi, but with a high risk of adverse infusion reactions. " 11/01/2021 - "Moderate-certainty evidence showed that pegloticase is probably beneficial for resolution of tophi in gout. " 09/01/2012 - "Two recent Phase III trials have found pegloticase to be effective in the management of treatment-failure gout. " 11/01/2011 - "For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option. "
2.	Pain (Aches) 07/01/2011 - "ES and SRMs in pegloticase group were as follows: VAS pain, 0.34 and 0.30; SF-36 pain, 0.69 and 0.57; patient global, 0.49 and 0.44. " 07/01/2011 - "Pegloticase group had significantly more improvement than placebo at 6 months, mean (SD): VAS pain, -9.2 (29.3) versus 1.9 (26.4), p=0.0002; SF-36 pain, 14.6 (25.6) versus -0.04 (21.1), p<0.0001; and patient global, -9.3 (26.5) versus 3.4 (22.8), p<0.0001. " 07/01/2013 - "The patient became wheel chair bound due to his pain and, at that point, the decision was made to initiate treatment with pegloticase. " 07/01/2012 - "Pegloticase therapy resulted in statistically significant and clinically meaningful improvements in PtGA, pain, physical function, and HRQOL." 07/01/2012 - "To assess the efficacy of pegloticase on pain, physical function, and health-related quality of life (HRQOL) in patients with refractory chronic gout. "
3.	Hyperuricemia 03/07/2014 - "In 11 of 12 TR, pUox fell rapidly and hyperuricemia recurred before dose 2. In all TR and NR, loss of response to pegloticase was accompanied by Ab to PEG, which was pre-existing in half of those who had no prior exposure to pegloticase. " 06/01/2008 - "Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout." 01/03/2008 - "PEG-uricase in the management of treatment-resistant gout and hyperuricemia." 07/01/2012 - "Pegloticase is effective in treating hyperuricemia and the clinical manifestations of gout in patients who cannot be adequately managed with conventional therapy." 07/15/1988 - "As an adjunct to cytolytic therapy for hematologic malignancies when protection from hyperuricemia is needed rapidly, PEG-uricase deserves further study."
4.	Gouty Arthritis 01/01/2017 - "A 56-year-old man with severe refractory tophaceous gouty arthritis was placed on low-dose azathioprine (50mg daily) in combination with pegloticase, with successful treatment after 98 weeks illustrated by significant improvement of caliper-measured tophi (77% decrease), resolution of gouty attacks, maintenance of low serum urate (sUA) level, absence of infusion reactions, and good toleration of the treatment by the patient. " 01/01/2023 - "This open-label, Phase 4 trial (PROTECT NCT04087720) examined safety and efficacy of pegloticase in 20 participants with KT > 1 year prior to enrollment and with uncontrolled gout (sUA ≥7 mg/dL, intolerance/inefficacy to urate lowering therapy, and ≥1 of the following: tophi, chronic gouty arthritis, ≥2 flares in past year) and functioning KT (estimated glomerular filtration rate [eGFR] ≥15 mL/min/1.73 m2 ) on stable immunosuppression therapy. " 11/01/2014 - "However, in patients with CKD, required allopurinol dosage reductions may limit efficacy; pegloticase requires further investigation in this population, and febuxostat has not been studied in patients with creatinine clearance<30 mL/min. This article reviews the risks and benefits associated with currently available pharmacologic agents for the management of acute and chronic gouty arthritis including urate-lowering therapy in patients with CKD. "
5.	Renal Insufficiency (Renal Failure) 01/21/2014 - "Patients with renal insufficiency were randomized to pegloticase 8 mg every 2 weeks (n = 42), pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20) for 6 months as defined by the study protocols. " 12/01/2011 - "Uricolytic drugs (pegloticase), which are currently being investigated, may be useful for the treatment of serious gout with tophus, especially in the presence of renal failure. " 05/01/2015 - "Administration of pegloticase in patients with comorbid chronic tophaceous gout and endstage renal failure requiring hemodialysis appears feasible." 07/15/1988 - "We report the first clinical use of PEG-modified Arthrobacter protoformiae uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma and renal insufficiency who was allergic to allopurinol. "

Related Drugs and Biologics

1.	Uric Acid (Urate)
2.	Methotrexate (Mexate)
3.	Urate Oxidase (Uricase)
4.	monomethoxypolyethylene glycol (MPEG)
5.	Febuxostat
6.	Polyethylene Glycols (Polyethylene Glycol)
7.	Azathioprine (Imuran)
8.	Antibodies
9.	Ethylene Glycol (Monoethylene Glycol)
10.	Bee Venoms (Bee Venom)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Subcutaneous Injections
4.	Renal Dialysis (Hemodialysis)
5.	Immunomodulation